TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)
Brief Summary: The purpose of this trial is to test the ability of the non-steroidal anti-inflammatory medications naproxen and celecoxib to delay or prevent the onset of AD and age-related cognitive decline.


Options:
A: Intervention Type: DRUG; Name: Naproxen Sodium (Aleve); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Celecoxib (Celebrex); Assigned to Arm(s): N/A
B: Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Celecoxib (Celebrex); Assigned to Arm(s): N/A
D: Arm Label: Selenium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Selenium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Selenium | Intervention Type: DRUG; Name: Selenium; Assigned to Arm(s): Placebo, Selenium

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #403 - Trial of Varicella Zoster Vaccine for the Prevention of Herpes Zoster and Its Complications
Brief Summary: The incidence and severity of HZ (or shingles), as well as the frequency and severity of its complications, increases markedly with increasing age. More than half of all cases occur in persons over the age of 60. Even without complications, HZ can interfere with an elderly patient's ability to perform essential activities of daily living, resulting in a loss of independence that is emotionally devastating and frequently irreversible. The most common complication of HZ in elderly persons is postherpetic neuralgia (PHN), which frequently results in disordered sleep, chronic fatigue, anxiety and severe depression. Antiviral therapy has a modest impact on the acute phase of HZ. However, it does not appear to prevent the development of PHN.

This study is a 5.5 year randomized, double-blind, placebo-controlled, efficacy trial to determine whether vaccination with live-attenuated Oka/Merck varicella-zoster decreases the incidence and/or severity of herpes zoster (HZ) and its complications in adults 60 years of age and older.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: Varicella-zoster vaccine | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Varicella-zoster vaccine; Assigned to Arm(s): Arm 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Arm 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: 13-valent Pneumococcal Conjugate Vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: 13-valent Pneumococcal Conjugate Vaccine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: 13-valent Pneumococcal Conjugate Vaccine | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Biological: 7vPnC | Intervention Type: BIOLOGICAL; Name: 13-valent Pneumococcal Conjugate Vaccine; Assigned to Arm(s): 1, 2, 3 | Intervention Type: BIOLOGICAL; Name: 7vPnC; Assigned to Arm(s): 4
C: Intervention Type: BIOLOGICAL; Name: M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®; Assigned to Arm(s): N/A
D: Intervention Type: BIOLOGICAL; Name: Measles, Mumps, Rubella and Chickenpox (live vaccine); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #424 - Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation
Brief Summary: PCI (optimal catheter-based coronary revascularization) + intensive medical therapy is superior to intensive medical therapy alone using the combined endpoint of all-cause mortality or nonfatal MI.


Options:
A: Arm Label: Saxagliptin 2.5 mg (A); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo matching Metformin, Drug: Metformin | Arm Label: Saxagliptin 5 mg (B); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo matching Metformin, Drug: Metformin | Arm Label: Saxagliptin 10 mg (C); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo matching Metformin, Drug: Metformin | Arm Label: Placebo (D); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matching Saxagliptin, Drug: Metformin | Arm Label: Open-Label Treatment Cohort (Direct Enrollees) (E); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 2.5 mg (A) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 5 mg (B) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 10 mg (C) | Intervention Type: DRUG; Name: Placebo matching Saxagliptin; Assigned to Arm(s): Placebo (D) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Placebo (D) | Intervention Type: DRUG; Name: Placebo matching Metformin; Assigned to Arm(s): Saxagliptin 10 mg (C), Saxagliptin 2.5 mg (A), Saxagliptin 5 mg (B) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Open-Label Treatment Cohort (Direct Enrollees) (E) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Open-Label Treatment Cohort (Direct Enrollees) (E), Placebo (D), Saxagliptin 10 mg (C), Saxagliptin 2.5 mg (A), Saxagliptin 5 mg (B)
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Intensive medical therapy, Procedure: Percutaneous Coronary Intervention (PCI) plus intensive medical therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intensive medical therapy | Intervention Type: PROCEDURE; Name: Intensive medical therapy; Assigned to Arm(s): 1, 2 | Intervention Type: PROCEDURE; Name: Percutaneous Coronary Intervention (PCI) plus intensive medical therapy; Assigned to Arm(s): 1
C: Arm Label: BI 1356; Type: ACTIVE_COMPARATOR; Interventions: Drug: BI 1356 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: BEHAVIORAL; Name: Insulin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #442 - Warfarin and Antiplatelet Therapy Study in Patients With Congestive Heart Failure (WATCH)
Brief Summary: Whether patients with chronic heart failure (CHF) should be anticoagulated is one of the oldest unresolved questions in cardiovascular therapeutics. Some authorities do not recommend anticoagulation for CHF patients in sinus rhythm, others recommend anticoagulation in patients with primary cardiomyopathy, and still others consider it more appropriate in patients with coronary artery disease (CAD). This absence of consensus reflects the lack of evidence in this area and different outlooks on the objectives of such therapy (e.g., prevention of arterial emboli or reduction in vascular events).


Options:
A: Arm Label: Rivaroxaban 2.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Other: Standard of care for heart failure and coronary artery disease | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Standard of care for heart failure and coronary artery disease | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban 2.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Standard of care for heart failure and coronary artery disease; Assigned to Arm(s): Placebo, Rivaroxaban 2.5 mg
B: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Enoxaparin placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: Rivaroxaban placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin placebo; Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939)
C: Arm Label: aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin | Arm Label: warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): aspirin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): warfarin
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin titrated to an INR of 2.5-3.0 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel 75 | Intervention Type: DRUG; Name: Warfarin titrated to an INR of 2.5-3.0; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Clopidogrel 75; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #442 - Warfarin and Antiplatelet Therapy Study in Patients With Congestive Heart Failure (WATCH)
Brief Summary: Whether patients with chronic heart failure (CHF) should be anticoagulated is one of the oldest unresolved questions in cardiovascular therapeutics. Some authorities do not recommend anticoagulation for CHF patients in sinus rhythm, others recommend anticoagulation in patients with primary cardiomyopathy, and still others consider it more appropriate in patients with coronary artery disease (CAD). This absence of consensus reflects the lack of evidence in this area and different outlooks on the objectives of such therapy (e.g., prevention of arterial emboli or reduction in vascular events).


Options:
A: Intervention Type: DRUG; Name: anticoagulation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: aspirin and dipyridamole; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: aspirin alone; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin titrated to an INR of 2.5-3.0 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel 75 | Intervention Type: DRUG; Name: Warfarin titrated to an INR of 2.5-3.0; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Clopidogrel 75; Assigned to Arm(s): 3
C: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: clopidogrel (SR25990); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #430 - Reducing The Efficacy-Effectiveness Gap In Bipolar Disorder
Brief Summary: Based on highly promising preliminary data, it is proposed to conduct a multi-site randomized controlled trial of a high-intensity ambulatory treatment program for bipolar disorder against standard office-based, physician-centered care. The major characteristics of this program are that it emphasizes (1) aggressive guideline-driven pharmacotherapy, (2) continuity of care with identified primary mental health nurse clinicians supported by psychiatrist back-up, and (3) patient education to improve treatment alliance and illness management skills.


Options:
A: Arm Label: A Helping Hand (AHH); Type: EXPERIMENTAL; Interventions: Behavioral: Self-care management | Arm Label: Usual Care (UC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-care management; Assigned to Arm(s): A Helping Hand (AHH)
B: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Reverse Colocated Integrated Care | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Reverse Colocated Integrated Care; Assigned to Arm(s): Intervention Group | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Control Group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Bipolar Disorder Program | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual (psychiatric) Care | Intervention Type: BEHAVIORAL; Name: Bipolar Disorder Program; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Usual (psychiatric) Care; Assigned to Arm(s): 2
D: Arm Label: TEAMcare treatment of diabetes; Type: ACTIVE_COMPARATOR; Interventions: Other: TEAMcare treatment of diabetes | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: TEAMcare treatment of diabetes; Assigned to Arm(s): TEAMcare treatment of diabetes

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To examine the effects of rigid gas permeable contact lenses on the progression of myopia (nearsightedness) in children

To determine what changes in the eyes cause certain eyes to progress in nearsightedness more slowly


Options:
A: Arm Label: Biofinity; Type: ACTIVE_COMPARATOR; Interventions: Device: Biofinity | Arm Label: Biofinity Multifocal D +1.50 add; Type: EXPERIMENTAL; Interventions: Device: Biofinity Multifocal D +1.50 add | Arm Label: Biofinity Multifocal D +2.50 add; Type: EXPERIMENTAL; Interventions: Device: Biofinity Multifocal D +2.50 add | Intervention Type: DEVICE; Name: Biofinity Multifocal D +1.50 add; Assigned to Arm(s): Biofinity Multifocal D +1.50 add | Intervention Type: DEVICE; Name: Biofinity Multifocal D +2.50 add; Assigned to Arm(s): Biofinity Multifocal D +2.50 add | Intervention Type: DEVICE; Name: Biofinity; Assigned to Arm(s): Biofinity
B: N/A
C: Arm Label: Contact Lens; Type: EXPERIMENTAL; Interventions: Device: Soft contact lenses | Arm Label: Spectacle; Type: ACTIVE_COMPARATOR; Interventions: Device: Spectacle | Intervention Type: DEVICE; Name: Soft contact lenses; Assigned to Arm(s): Contact Lens | Intervention Type: DEVICE; Name: Spectacle; Assigned to Arm(s): Spectacle
D: Intervention Type: DRUG; Name: 7-methylxanthine; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Follow-up Visit of High Risk Infants
Brief Summary: The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may affect infant neurodevelopment.


Options:
A: Arm Label: PNEUMOSTEM®; Type: EXPERIMENTAL; Interventions: Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells | Intervention Type: BIOLOGICAL; Name: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells; Assigned to Arm(s): PNEUMOSTEM®
B: Arm Label: infusions; Type: EXPERIMENTAL; Interventions: Biological: infusion of autologous cord blood | Arm Label: historical control; Type: OTHER; Interventions: Other: Neurodevelopmental outcomes | Intervention Type: BIOLOGICAL; Name: infusion of autologous cord blood; Assigned to Arm(s): infusions | Intervention Type: OTHER; Name: Neurodevelopmental outcomes; Assigned to Arm(s): historical control
C: Arm Label: Pneumostem®; Type: N/A; Interventions: Biological: Pneumostem® | Intervention Type: BIOLOGICAL; Name: Pneumostem®; Assigned to Arm(s): Pneumostem®
D: Arm Label: Registry Cohort; Type: N/A; Interventions: Other: No Intervention | Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): Registry Cohort

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)
Brief Summary: This trial was to determine whether giving low-dose indomethacin to infants weight 500 to 999 grams (approximately 1 to 2 pounds) at birth improves their survival without cerebral palsy or developmental problems at 18 to 22 months of age.


Options:
A: Arm Label: Darbepoetin alfa injection; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa Injection | Arm Label: erythropoietin alfa injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: erythropoietin alfa injection | Arm Label: placebo/control; Type: PLACEBO_COMPARATOR; Interventions: Drug: sham injection | Intervention Type: DRUG; Name: Darbepoetin Alfa Injection; Assigned to Arm(s): Darbepoetin alfa injection | Intervention Type: DRUG; Name: erythropoietin alfa injection; Assigned to Arm(s): erythropoietin alfa injection | Intervention Type: DRUG; Name: sham injection; Assigned to Arm(s): placebo/control
B: Arm Label: Erythropoietin; Type: EXPERIMENTAL; Interventions: Drug: Recombinant human Erythropoietin | Arm Label: saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline | Intervention Type: DRUG; Name: Recombinant human Erythropoietin; Assigned to Arm(s): Erythropoietin | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): saline
C: Arm Label: preterm ESA recipients; Type: N/A; Interventions: N/A | Arm Label: preterm controls; Type: N/A; Interventions: N/A | Arm Label: term controls; Type: N/A; Interventions: N/A
D: Arm Label: Indomethacin; Type: EXPERIMENTAL; Interventions: Drug: indomethacin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)
Brief Summary: This trial was to determine whether giving low-dose indomethacin to infants weight 500 to 999 grams (approximately 1 to 2 pounds) at birth improves their survival without cerebral palsy or developmental problems at 18 to 22 months of age.


Options:
A: Arm Label: G-CSF; Type: EXPERIMENTAL; Interventions: Drug: rh G-CSF | Arm Label: EPO; Type: EXPERIMENTAL; Interventions: Drug: rh EPO | Arm Label: G-CSF and EPO; Type: EXPERIMENTAL; Interventions: Drug: recombinant human G-CSF, and rhEPO, Drug: rh G-GSF and rh EPO together | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: recombinant human G-CSF, and rhEPO; Assigned to Arm(s): G-CSF and EPO | Intervention Type: DRUG; Name: rh G-CSF; Assigned to Arm(s): G-CSF | Intervention Type: DRUG; Name: rh EPO; Assigned to Arm(s): EPO | Intervention Type: DRUG; Name: rh G-GSF and rh EPO together; Assigned to Arm(s): G-CSF and EPO | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: preterm ESA recipients; Type: N/A; Interventions: N/A | Arm Label: preterm controls; Type: N/A; Interventions: N/A | Arm Label: term controls; Type: N/A; Interventions: N/A
C: Arm Label: Darbepoetin alfa injection; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa Injection | Arm Label: erythropoietin alfa injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: erythropoietin alfa injection | Arm Label: placebo/control; Type: PLACEBO_COMPARATOR; Interventions: Drug: sham injection | Intervention Type: DRUG; Name: Darbepoetin Alfa Injection; Assigned to Arm(s): Darbepoetin alfa injection | Intervention Type: DRUG; Name: erythropoietin alfa injection; Assigned to Arm(s): erythropoietin alfa injection | Intervention Type: DRUG; Name: sham injection; Assigned to Arm(s): placebo/control
D: Arm Label: Indomethacin; Type: EXPERIMENTAL; Interventions: Drug: indomethacin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Trial Comparing Adjuvant Clodronate Therapy vs Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Hormonal Therapy or No Therapy
Brief Summary: RATIONALE: Clodronate may be effective in preventing the spread of cancer to the bones and other parts of the body. It is not yet known whether clodronate is more effective alone or combined with chemotherapy and /or hormonal therapy in preventing metastatic breast cancer.

PURPOSE: Randomized phase III trial to determine the effectiveness of clodronate with or without chemotherapy and /or hormonal therapy in preventing metastases in women who have stage I or stage II breast cancer.


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: risedronate (including placebo) | Intervention Type: DRUG; Name: risedronate (including placebo); Assigned to Arm(s): A
B: Arm Label: AZ (Arimidex+Zoledronate); Type: ACTIVE_COMPARATOR; Interventions: Drug: anastrozole, Drug: zoledronic acid, Other: goserelin | Arm Label: TZ (Tamoxifen+Zoledronate); Type: ACTIVE_COMPARATOR; Interventions: Drug: tamoxifen, Drug: zoledronic acid, Other: goserelin | Arm Label: AC (Arimidex Control); Type: ACTIVE_COMPARATOR; Interventions: Drug: anastrozole, Other: goserelin | Arm Label: TC (Tamoxifen Control); Type: ACTIVE_COMPARATOR; Interventions: Drug: tamoxifen, Other: goserelin | Intervention Type: DRUG; Name: tamoxifen; Assigned to Arm(s): TC (Tamoxifen Control), TZ (Tamoxifen+Zoledronate) | Intervention Type: DRUG; Name: anastrozole; Assigned to Arm(s): AC (Arimidex Control), AZ (Arimidex+Zoledronate) | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): AZ (Arimidex+Zoledronate), TZ (Tamoxifen+Zoledronate) | Intervention Type: OTHER; Name: goserelin; Assigned to Arm(s): AC (Arimidex Control), AZ (Arimidex+Zoledronate), TC (Tamoxifen Control), TZ (Tamoxifen+Zoledronate)
C: Arm Label: Arm 1: Clodronate; Type: EXPERIMENTAL; Interventions: Drug: clodronate | Arm Label: Arm 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: clodronate; Assigned to Arm(s): Arm 1: Clodronate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Arm 2: Placebo
D: Arm Label: Ibandronic Acid; Type: EXPERIMENTAL; Interventions: Drug: ibandronate sodium | Arm Label: Zoledronic Acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: zoledronic acid, Drug: Zolendronic Acid | Intervention Type: DRUG; Name: ibandronate sodium; Assigned to Arm(s): Ibandronic Acid | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): Zoledronic Acid | Intervention Type: DRUG; Name: Zolendronic Acid; Assigned to Arm(s): Zoledronic Acid

Answer: C